MedTrace Logo

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

NCT00225589 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 840

Last updated 2010-11-19

No results posted yet for this study

Summary

The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.

Conditions

  • Hypercholesteremia

Interventions

DRUG

Rosuvastatin calcium

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Crestor Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • United States
  • Belgium
  • Czechia
  • Finland
  • France
  • Germany
  • Netherlands
  • Norway

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225589 on ClinicalTrials.gov